Listed for reference — companies are not ranked in any particular order.
| Market Size 2024 | US$ 4,725.4 Million |
| Market Size 2031 | US$ 10,151.9 Million |
| CAGR 2025–2031 | 11.6% |
| Segments | By Therapy Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors, Cancer Vaccines, Gene Therapy, Other Therapy Types) | By Indication (Blood Cancer, Lung Cancer, Breast Cancer, Colorectum Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Duct Cancer, Thyroid Cancer, Other Indications) | By End User (Hospital Pharmacies, Retail Pharmacies, Online Stores) | By End User (Hospital Pharmacies, Retail Pharmacies, Online Stores) |
| Geographies | South and Central America (Brazil, Argentina, Peru, Chile, Colombia) |
| Deliverables | Historical analysis with CAGR · PEST & SWOT analysis · Market Size at Global, Regional, and Country Levels · Competitive heat map · Company profiles · Excel dataset |
| Report Code | BMIPUB00033515 |
| Lead Analyst | Krishna Sunthwal — Analyst, Research · View Profile |
Gain actionable insights with 205 pages of in-depth South and Central America Cancer Targeted Therapy Market, including historical trends, 7-year market forecasts, SWOT analysis, competitive landscapes, and downloadable Excel datasets in a single comprehensive package.